Stay updated on PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial
Sign up to get notified when there's something new on the PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial page.

Latest updates to the PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial page
- Check7 days agoChange DetectedThe record describes a completed early-phase melanoma trial combining nivolumab, CD137 agonism, and adoptive TIL therapy. It includes the study’s eligibility criteria, treatment plan, safety outcome, investigators, and dates.SummaryDifference55%

- Check14 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide NIH announcement about a terminology transition appears above the ClinicalTrials.gov 403 error page.SummaryDifference1%

- Check28 days agoChange DetectedThe footer’s site revision changed from v3.7.1 to v3.7.2; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the trial content. A minimal header and footer with a Home button are shown, indicating an access issue rather than content updates.SummaryDifference20%

Stay in the know with updates to PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial page.